Literature DB >> 16534681

Prediction of hepatic encephalopathy development in patients with severe acute hepatitis.

Yasuhiro Takikawa1, Ryujin Endo, Kazuyuki Suzuki, Kenji Fujiwara, Masao Omata.   

Abstract

To identify factors predicting the development of hepatic encephalopathy, 164 patients with severe acute hepatitis (SAH), defined as acute hepatitis having a prolonged prothrombin time (PT) of < 40% activity but without hepatic encephalopathy, were prospectively observed at 57 major liver centers in Japan. From the data of 65 patients enrolled from 1997 to 1998, a prediction equation was developed by multiple logistic regression analysis and prospectively evaluated using the data of 99 patients since 1999. Of the 164 patients with SAH, 51 (31%) developed hepatic encephalopathy. From the etiologic viewpoint, the percentages of patients developing encephalopathy were highest in non-A-E hepatitis (41.9%). A predictive model, logit(p) = 0.084 x age (year)+ 0.129 x serum total bilirubin (TB, in mg/dL)-0.158 x prothrombin time (%)-2.434, was developed. In conclusion, old age, prolonged PT, elevation of TB, and non-A-E hepatitis are potential risk factors for developing encephalopathy in SAH.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16534681     DOI: 10.1007/s10620-006-3138-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  14 in total

1.  Burden of liver disease in the United States: summary of a workshop.

Authors:  W Ray Kim; Robert S Brown; Norah A Terrault; Hashem El-Serag
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

2.  Usefulness of plasma exchange plus continuous hemodiafiltration to reduce adverse effects associated with plasma exchange in patients with acute liver failure.

Authors:  T Sadahiro; H Hirasawa; S Oda; H Shiga; K Nakanishi; N Kitamura; T Hirano
Journal:  Crit Care Med       Date:  2001-07       Impact factor: 7.598

3.  Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure.

Authors:  M Yoshiba; K Inoue; K Sekiyama; I Koh
Journal:  Artif Organs       Date:  1996-11       Impact factor: 3.094

4.  Quality of life in adult Japanese patients undergoing liver transplants overseas.

Authors:  Y Kita; K Umeshita; M Gotoh; M Sakon; M Monden; T Ichida; K Ota
Journal:  Transplant Proc       Date:  1996-06       Impact factor: 1.066

5.  The liver during and after fulminant hepatitis.

Authors:  J T Horney; J T Galambos
Journal:  Gastroenterology       Date:  1977-10       Impact factor: 22.682

6.  Fulminant hepatic failure. Presumable contribution to halothane.

Authors:  C Trey; L Lipworth; T C Chalmers; C S Davidson; L S Gottlieb; H Popper; S J Saunders
Journal:  N Engl J Med       Date:  1968-10-10       Impact factor: 91.245

Review 7.  Present status of fulminant hepatitis in Japan (1989-1991)

Authors:  Y Muto
Journal:  Gastroenterol Jpn       Date:  1993-03

8.  Clinical epidemiology of fulminant hepatitis in Japan before the substantial introduction of liver transplantation: an analysis of 1309 cases in a 15-year national survey.

Authors:  Shunichi Sato; Kazuyuki Suzuki; Yasuhiro Takikawa; Ryujin Endo; Masao Omata
Journal:  Hepatol Res       Date:  2004-11       Impact factor: 4.288

9.  Etiology of fulminant viral hepatitis in Greece.

Authors:  G Papaevangelou; N Tassopoulos; A Roumeliotou-Karayannis; C Richardson
Journal:  Hepatology       Date:  1984 May-Jun       Impact factor: 17.425

Review 10.  Donor and recipient outcomes after adult living donor liver transplantation.

Authors:  Abhinav Humar
Journal:  Liver Transpl       Date:  2003-10       Impact factor: 5.799

View more
  5 in total

1.  Serum Procalcitonin in Patients with Acute Liver Failure.

Authors:  Takaaki Sugihara; Masahiko Koda; Toshiaki Okamoto; Kenichi Miyoshi; Tomomitsu Matono; Kenji Oyama; Keiko Hosho; Jun-Ichi Okano; Hajime Isomoto
Journal:  Yonago Acta Med       Date:  2017-03-09       Impact factor: 1.641

2.  Clinical impact of serum transforming growth factor-alpha mRNA as a predictive biomarker for the prognosis of fulminant hepatitis.

Authors:  Norimasa Miura; Hiroko Kabashima; Mika Shimizu; Reina Sato; Tomoe Tsukamoto; Tomomi Harada; Shunsaku Takahashi; Ryujin Endo; Nobuaki Nakayama; Yasuhiro Takikawa; Satoshi Mochida; Kazuyuki Suzuki; Junichi Hasegawa; Goshi Shiota
Journal:  Hepatol Int       Date:  2008-04-09       Impact factor: 6.047

3.  Arterial steroid injection therapy can inhibit the progression of severe acute hepatic failure toward fulminant liver failure.

Authors:  Kazuhiro Kotoh; Munechika Enjoji; Makoto Nakamuta; Tsuyoshi Yoshimoto; Motoyuki Kohjima; Shusuke Morizono; Shinsaku Yamashita; Yuki Horikawa; Kengo Yoshimitsu; Tsuyoshi Tajima; Yoshiki Asayama; Kousei Ishigami; Masakazu Hirakawa
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

4.  Hemodynamic Alteration in the Liver in Acute Hepatitis: A Quantitative Evaluation Using Computed Tomographic Perfusion.

Authors:  Akihiro Nishie; Yasuhiro Ushijima; Yukihisa Takayama; Nobuhiro Fujita; Yuichiro Kubo; Keisuke Ishimatsu; Daisuke Tsurumaru; Motoyuki Kohjima; Kousei Ishigami
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

5.  Clinical Factors and Viral Load Influencing Severity of Acute Hepatitis A.

Authors:  Hyun Woong Lee; Dong-Yeop Chang; Hong Ju Moon; Hye Young Chang; Eui-Cheol Shin; June Sung Lee; Kyung-Ah Kim; Hyung Joon Kim
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.